# Internal Review - Round 1

**Reviewer:** Claude Code (internal)
**Paper:** Follow the Money or Follow the Crime? Civil Asset Forfeiture Reform and Drug Overdose Mortality

---

## PART 1: CRITICAL REVIEW

### 1. Identification and Empirical Design

**Strengths:** The staggered DiD design using Callaway-Sant'Anna (2021) with never-treated controls is appropriate. The paper correctly identifies 34 treated jurisdictions (33 states + DC) and 17 never-reformed controls. The institutional argument for exogeneity of reform timing (civil liberties motivation, not drug outcomes) is compelling.

**Concerns:**
- The 2019 cohort (8 jurisdictions) has only one post-treatment observation (t = G_s). While the CS-DiD estimator can use this, the ATT(g=2019, t=2019) estimates will be very imprecise. The paper acknowledges this limitation.
- Event time +5 is identified solely from Minnesota. The paper now correctly discloses this, but it remains a limitation — the long-run effect is essentially a case study of one state.
- The parallel trends assumption rests on 4 pre-treatment coefficients (e=-5 through e=-2), which is adequate but not abundant.

### 2. Inference and Statistical Validity

- Standard errors are clustered at the state level throughout. With 51 clusters, this is adequate.
- The overall ATT of -1.00 (SE=1.89) is statistically insignificant. The paper appropriately frames this as suggestive.
- Randomization inference (500 permutations) yields RI p=0.846, confirming the imprecision.
- Sample sizes are now reported in all tables.

### 3. Robustness and Alternative Explanations

- Placebo test (pre-period fake treatment) yields null. Good.
- Leave-one-out jackknife identifies DE, MD, DC as influential — all high-forfeiture small jurisdictions.
- Sun-Abraham estimates align qualitatively with CS-DiD. Good cross-validation.
- Not-yet-treated controls yield similar ATT (-0.90 vs -1.00). Robust.
- Missing: no concurrent policy controls (naloxone access, PDMP, Good Samaritan). The paper discusses this threat qualitatively but doesn't control for it directly.

### 4. Contribution and Literature Positioning

The paper fills a genuine gap: no prior work links forfeiture reform to health outcomes. The positioning relative to Kantor et al. (2021), Lee and Mocan (2023), and Caso and Sloan (2022) is clear.

### 5. Results Interpretation

- The abstract and introduction now correctly state that *least*-dependent states show the largest effects.
- The welfare calculation ($89B) is extreme and appropriately caveated. Consider moving to appendix or shortening.
- The dose-response finding (transparency > abolition) is interesting but the mechanism story is speculative.

### 6. Actionable Revision Requests

**Must-fix:**
1. None remaining — sample counts, pre-treatment coefficient counts, and significance stars are now consistent.

**High-value improvements:**
1. Consider controlling for concurrent state-level drug policies (PDMPs, naloxone access laws) as a robustness check.
2. Report the number of cohorts contributing to each event-time estimate.
3. Consider trimming the welfare calculation section, which is speculative given the imprecision.

**Optional:**
1. Add a map figure showing reform adoption geography.
2. Report Goodman-Bacon decomposition weights.

### 7. Overall Assessment

**Strengths:** Novel question, clean identification design, transparent about limitations, well-written prose, appropriate use of modern DiD methods, honest null result framing.

**Weaknesses:** The main estimate is statistically insignificant. The long-run effect is driven by a single state. The mechanism (enforcement reallocation) is hypothesized but not directly tested.

The paper makes a contribution by being the first to link forfeiture reform to health outcomes, and the honest engagement with null results is a strength rather than a weakness.

---

DECISION: MINOR REVISION
